, Volume 26, Issue 4, pp 1133–1137 | Cite as

W.E.W. Roediger: Causative factors of ulcerative colitis and Crohn’s disease: an exploratory guide

Wakefield Press 2016 (reprinted 2017). 106 pp. ISBN 978 174305 433 8
  • Michael W. Whitehouse
Book Review


This monograph provides the background for new developments in gastroenterological pharmacology, particularly focussing on the two chronic inflammatory bowel diseases, ulcerative colitis (UC) and Crohn’s disease (CD). These currently cause significant morbidity but largely elude satisfactory treatment. This is a challenge to drug designers and experimental physiologists alike. Their efforts will be much enhanced by further understanding the aspects of molecular pathogenesis and physiological dysregulation outlined in this valuable and timely survey.


Crohn’s disease Ulcerative colitis Pathogenesis Nitric oxide Hydrogen sulphide Therapeutics 





Crohn’s disease


Eosinophilic peroxidase


Gut dysbiosis symptoms




Hydrogen cyanide


Hydrogen sulphide (or soluble salts thereof)


Inflammatory bowel diseases


Nitric oxide


Thiocyanate anion


Hypothiocyanite, the antibacterial (per)oxidation product of SCN


Ulcerative colitis


Compliance with ethical standards

Conflict of interest

MWW declares no competing interests exist.


  1. Davies NM (1995) Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 38:1311–1321CrossRefPubMedGoogle Scholar
  2. Dixon MF (2009) Chronic inflammatory disorders (Alimentary tract). In: Underwood JCE, Cross SS (eds) General and systemic pathology, 5th edn. Churchill Livingstone, Edinburgh, pp 385–390Google Scholar
  3. Evans AS (1993) Causation and disease. A chronological journey. Plenum Medical Book Co., New York, p 238CrossRefGoogle Scholar
  4. Giampaolo C, Gray AT, Olshen RA, Szabo S (1991) Predicting chemically induced duodenal ulcer and adrenal necrosis with classification trees. Proc Natl Acad Sci 88:6298–6302CrossRefPubMedGoogle Scholar
  5. Holmes ESL (2017) Heal your gut. Murdoch Books (Allen & Unwin), LondonGoogle Scholar
  6. Jacobs G, Kjaer J (1997) Beat Candida through diet. A complete dietary program for sufferers of Candidiasis. Vermilion (Random House), LondonGoogle Scholar
  7. Lindsay R, Gregory MS, Yazbek R, Butler RN, Howarth GN (2010) Orally administered emu oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis. Br J Nutr 104:513–519CrossRefPubMedGoogle Scholar
  8. Maier L, Pruteanu M, Kuhn M, Zeiler G, Telzerow A, Anderson EE et al (2018) Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. CrossRefPubMedPubMedCentralGoogle Scholar
  9. Peters RA (1963) Biochemical lesions and lethal synthesis. Pergamon Press, Oxford, p 321Google Scholar
  10. Rouch JD, Scott A, Lei NY, Solorzano-Vargas RS, Wang J, Hanson EM et al (2015) Development of functional microfold (M) cells from intestinal stem cells in primary human enteroids. PLoS One 11:e0148216CrossRefGoogle Scholar
  11. Rubin J, Remedios D (2005) The great physician’s Rx for Health & Wellness. Nashville TN. Nelson Books, pp 370 (The first author, aged 19, was totally incapacitated with CD, failed to respond to allopathic and other prescribed treatments but regained full-health through nutritional medicine)Google Scholar
  12. Sisson G, Bjarnason I (2011) Serious upper gastrointestinal complications of NSAIDs and COX-2 selective agents. Inflammopharmacol 19:183–186CrossRefGoogle Scholar
  13. Svartz N (1942) Salazopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. J Int Med 110:577–598Google Scholar
  14. Thomas GAO, Rhodes J, Green JT, Richardson C (2000) Role of smoking in inflammatory bowel disease: implication for therapy. Postgrad Med J 76:273–279CrossRefPubMedPubMedCentralGoogle Scholar
  15. Turner A, Hancock G, Wells J, Whitehouse M (2015) Traditional medicinal oils sourced from birds.: anti-inflammatories and potential immunoregulants. Progr Drug Res 70:155–178Google Scholar
  16. Vitetta L, Briskey D, Alford H, Hall S, Coulson S (2014a) Probiotics, prebiotics and the gastrointestinal tract in health and disease. Inflammopharmacology 22:135–154CrossRefPubMedGoogle Scholar
  17. Vitetta L, Manuel R, Zhou J, Linnane A, Hall S, Coulson S (2014b) The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures. Pharmaceuticals 7:954–989CrossRefPubMedPubMedCentralGoogle Scholar
  18. Whitehouse MW (1964) Some biochemical and pharmacological properties of anti-inflammatory drugs. Progr Drug Res 8:321–429Google Scholar
  19. Whitehouse MW (1982) Rat polyarthritis: induction with adjuvants composed of various mycobacteria (and oils) from the environment. J Rheumatol 9:494–501PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Michael W. Whitehouse
    • 1
    • 2
  1. 1.School of MedicineGriffith UniversityStones CornerAustralia
  2. 2.SouthportAustralia

Personalised recommendations